Form 8-K - Current report:
SEC Accession No. 0001193125-25-119408
Filing Date
2025-05-14
Accepted
2025-05-14 08:09:09
Documents
14
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916904d8k.htm   iXBRL 8-K 25620
2 EX-99.1 d916904dex991.htm EX-99.1 39814
  Complete submission text file 0001193125-25-119408.txt   198667

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA klrs-20250514.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE klrs-20250514_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE klrs-20250514_pre.xml EX-101.PRE 11708
16 EXTRACTED XBRL INSTANCE DOCUMENT d916904d8k_htm.xml XML 3790
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Filer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39409 | Film No.: 25942725
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)